COVID-19 Pneumonia
234
8
9
104
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
15 trials with published results (6%)
Research Maturity
104 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.0%
14 terminated out of 234 trials
88.1%
+1.6% vs benchmark
16%
38 trials in Phase 3/4
14%
15 of 104 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 104 completed trials
Clinical Trials (234)
ARrest RESpiraTory Failure From PNEUMONIA
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Respiratory Muscle Training and Walking Exercise in Women Recovering From COVID-19 Pneumonia
COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients
Imbalances of Regional Pulmonary Ventilation in Patients With Post-acute-COVID-19
Hepatitis B Virus Reactivation in COVID-19
Corona Virus Disease 2019 Cohort Study
HRQOL of Life After ECMO Due to COVID-19.
Tofacitinib for Treatment of Moderate COVID-19
The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients
Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19.
Evaluation of Postmortem Pulmonary Interstitial Fibrosis Severity and EGFR Positivity in Covid-19 Pneumonia